ABCG2 and cancer: KSQ‐4279, an USP1 inhibitor in clinical trial, widely reversed multidrug resistance in refractory cancers by competing for the drug‐binding pockets of ABCB1/ABCG2/ABCC1 and blocking chemotherapeutic drugs’ efflux.